Use systemic immunosupression with great caution experts advise

Article

Systemic immunosuppression following corneal transplantation should be administered only under strict medical surveillance.

Systemic immunosuppression following corneal transplantation should be administered only under strict medical surveillance, according to specialists speaking at the ESCRS Winter Refractive Surgery Meeting's Cornea Day in Athens, Greece.

Jorge L. Alio, MD commented that patients should be made aware that lifelong immunosuppression is unavoidable in some cases. He emphasized that it is especially important to understand that the elderly are more at risk of severe complications and that it may induce fertility problems in women.

However, according to Nikolaos Papadopoulos, MD, the main danger comes in the form lung aspergillosis, a potentially fatal condition. He cited one case where a 65-year old woman, treated with oral cyclosporine, was found to have the condition after a second graft was rejected. Fortunately, in this case they were able to treat the disease and a third graft was successful.

As an alternative, Dr Papadopoulos suggests that topical immunosupression is a viable alternative to systemic treatment. However Dr Alio disagreed, saying that it is simply not as effective over the long-term and is not able to reach the anterior chamber, adding that he personally prefers to use tacrolimus in a 1% concentration.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jeremiah Tao, MD, FACS, discusses his Egyptian Ophthalmological Society keynote, which focused on risk management and avoiding surgical complications in oculofacial surgery
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
© 2025 MJH Life Sciences

All rights reserved.